Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Feb 27;11(3):555.
doi: 10.3390/vaccines11030555.

Post-COVID-19 Fungal Infection in the Aged Population

Affiliations
Review

Post-COVID-19 Fungal Infection in the Aged Population

Vivek P Chavda et al. Vaccines (Basel). .

Abstract

Coronavirus disease 2019 (COVID-19) infection is currently a great cause of concern for the healthcare sector around the globe. SARS-CoV-2 is an RNA virus that causes a serious infection that is associated with numerous adverse effects and multiple complications associated with different organs and systems during its pathogenic cycle in humans. Individuals affected by COVID-19, especially elderly populations and immunocompromised people, are greatly vulnerable to opportunistic fungal pathogens. Aspergillosis, invasive candidiasis, and mucormycosis are widespread fungal coinfections in COVID-19 patients. Other fungal infections that are rare but are exhibiting increased incidence in the current scenario include infections caused by Pneumocystis jirovecii, Histoplasma sp., Cryptococcus sp., etc. By producing virulent spores, these pathogens increase the severity of the disease and increase the morbidity and fatality rates in COVID-19 patients globally. These infections generally occur in patients recovering from COVID-19 infection, resulting in rehospitalization. Older and immunocompromised individuals are at higher risk of developing opportunistic fungal infections. This review focuses on understanding the opportunistic fungal infections prevalent in COVID-19 patients, especially elderly people. We have also highlighted the important preventive methods, diagnostic approaches, and prophylactic measures for fungal infections.

Keywords: COVID-19; aspergillosis; coinfection; fungal infections; invasive candidiasis; mucormycosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Mechanism of the pathogenesis of invasive aspergillosis, mucormycosis, and cryptococcus fungal infections and their complications (Created using Biorender.com).

Similar articles

Cited by

References

    1. Seyedjavadi S.S., Bagheri P., Nasiri M.J., Razzaghi-Abyaneh M., Goudarzi M. Fungal Infection in Co-Infected Patients With COVID-19: An Overview of Case Reports/Case Series and Systematic Review. Front. Microbiol. 2022;13:1–13. doi: 10.3389/fmicb.2022.888452. - DOI - PMC - PubMed
    1. Sanyaolu A., Okorie C., Marinkovic A., Patidar R., Younis K., Desai P., Hosein Z., Padda I., Mangat J., Altaf M. Comorbidity and Its Impact on Patients with COVID-19. SN Compr. Clin. Med. 2020;2:1069–1076. doi: 10.1007/s42399-020-00363-4. - DOI - PMC - PubMed
    1. Bhatt K., Agolli A., Patel M.H., Garimella R., Devi M., Garcia E., Amin H., Domingue C., Del Castillo R.G., Sanchez-Gonzalez M. High Mortality Co-Infections of COVID-19 Patients: Mucormycosis and Other Fungal Infections. Discoveries. 2021;9:e126. doi: 10.15190/d.2021.5. - DOI - PMC - PubMed
    1. Coskun A.S., Durmaz S.O. Fungal Infections in COVID-19 Intensive Care Patients. Pol. J. Microbiol. 2021;70:395. doi: 10.33073/pjm-2021-039. - DOI - PMC - PubMed
    1. Hughes S., Troise O., Donaldson H., Mughal N., Moore L.S.P. Bacterial and Fungal Coinfection among Hospitalized Patients with COVID-19: A Retrospective Cohort Study in a UK Secondary-Care Setting. Clin. Microbiol. Infect. 2020;26:1395. doi: 10.1016/j.cmi.2020.06.025. - DOI - PMC - PubMed

LinkOut - more resources